Growth momentum Tempus, now a Tempus company under IT services and consulting, reports meaningful quarterly growth with revenue increases and improved EBITDA, indicating a viable opportunity to position advanced analytics, AI-driven optimization, and integration services for expanding customer bases.

Genomics expansion Recent launches of GenomeNext and OneOme pharmacogenomics testing demonstrate a strategic push into genomics and precision medicine, suggesting up-sell potential for data platforms, interoperability, and workflow automation solutions tailored to life sciences providers and hospitals.

Data and AI focus The tech stack includes AI and data tooling such as LangChain, Rust, Marketo, and Ansible, implying a receptiveness to modernization projects, API integrations, and secure DevOps practices that could be offered to improve data pipelines and customer experience platforms.

Strategic acquisitions Mergers and acquisitions activity in the ecosystem, including past and reported intent to acquire genetics firms, points to a market hungry for interoperability, private equity-backed growth, and comprehensive data-enabled service offerings that your team can align with as a partner or supplier.

Partner and extend Industry peers mentioned in comparable company profiles operate at larger scales with extensive lab networks; a partnership approach around technology enablement, cloud integration, and managed services could position your capabilities as a complementary vendor to accelerate Tempus’ expansion in genomics-driven care.